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Nonsteroidal anti-inflammatory drugs (NSAIDs) have
been used for relieving the inflammation caused by
various physiologic or pathologic conditions for more
than 100 years. An early clinical study demonstrated
that NSAIDs may attenuate cancer progression in
patients with familial adenomatous polyposis and
Gardner’s syndrome [1]. A benefit of NSAID use in re-
ducing cancer risk is supported by a large, population-
based epidemiologic investigation which concluded
that low-dose and regular use of NSAIDs reduced the
risk of fetal colon cancer [2]. Subsequent studies also
suggested that NSAIDs are effective in the prevention
of tumorigenesis of human cancers including lung,
breast, prostate, and esophagus [3–6].
The main target of NSAIDs was first described by
Sir John Vane in 1971 [7]. He reported that many
NSAIDs inhibited the enzymatic activity of prosta-
glandin G/H synthase (also named cyclooxygenase).
Cyclooxygenases (COXs) are the rate-limiting enzymes
that catalyze the conversion of arachidonic acid to
prostaglandins (PGs). Two COX isoforms with dis-
tinct tissue distributions and physiologic functions
have been identified in mammalian cells [8,9]. COX-1
is constitutively expressed in many tissues and plays
an important role in the control of homeostasis [10].
Conversely, COX-2 is an inducible enzyme and is
activated in response to extracellular stimuli such as
growth factors and proinflammatory cytokines [11].
In 1994, Eberhart et al showed that COX-2, but not
COX-1, is selectively upregulated in colorectal can-
cers [12]. Subsequent investigations indicated that
overexpression of COX-2 is frequently found in many
cancers including colon, lung, breast, pancreas, and
head and neck cancers [13–17], and is usually associ-
ated with poor prognosis and short survival.
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Epidemiological studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the
incidence and mortality of several types of human cancer. However, the molecular mechanisms
by which NSAIDs exert their chemopreventive and anticancer effects are not fully understood.
Cyclooxygenase 1 (COX-1) and COX-2 are the main targets for NSAIDs. Recent studies demon-
strate that COX-2 is overexpressed in many human cancers and may promote tumorigenesis via:
(1) stimulation of cancer cell proliferation; (2) increase of tumor angiogenesis; (3) prevention of
cancer cell apoptosis; (4) modulation of immunoregulatory reactions; and (5) enhancement of
tumor metastasis. NSAIDs may target the signaling molecules (from upstream activators to down-
stream effectors) involved in these mechanisms to attenuate the development and progression of
cancer. In this review, we discuss the recent findings with regard to the mechanisms by which
NSAIDs inhibit tumorigenesis and will specifically focus on the elucidation of NSAID-induced
inhibition of tumor metastasis.
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The contribution of COX-2 to tumorigenesis has
been intensively studied. Several mechanisms are con-
sidered to mediate the tumorigenic activity of COX-2.
First, PGs, the metabolites of COX-2, are growth pro-
moters and may directly stimulate proliferation of
cancer cells [18,19]. Second, COX-2 is an angiogenic
stimulator and has been shown to increase the produc-
tion of angiogenic factors and migration of endothe-
lial cells [20,21]. Third, COX-2-derived PGs function
as antiapoptotic molecules that may prevent apoptosis
induced by anticancer drugs [22,23]. Fourth, PGs are
immunoregulatory molecules and have been found
to suppress the antitumor activity of natural killer
cells and macrophages [24]. Finally, COX-2 expression
may increase the invasive ability of tumor cells to
promote cancer metastasis [25,26].
ANTI-CANCER EFFECTS OF NSAIDS
As aforementioned, COX-2 and PGs contribute to the
development of tumors via multiple mechanisms. It
seems reasonable that NSAIDs may target the signal-
ing molecules involved in these mechanisms to inhibit
tumorigenesis. A number of excellent reviews have
discussed the anticancer effects of NSAIDs in detail
[27–30]. So, I will briefly summarize the molecular
mechanisms underlying NSAID-induced tumor inhibi-
tion below and focus specifically on the antimetastatic
action of NSAIDs.
Suppression of proliferation via inhibition
of cell cycle progression
NSAIDs have been shown to repress the expression or
activity of cell cycle promoters. For example, expres-
sions of cyclin D1, A, and B and the enzymatic activi-
ties of cyclin E/cyclin-dependent kinase 2 (CDK2) and
cyclin B1/CDK1 are inhibited by NSAIDs [31–34].
These inhibitions lead to growth arrest in vitro and
tumor regression in vivo. In addition to inhibition of
cell cycle promoters, NSAIDs may also suppress cell
proliferation by upregulating negative cell cycle con-
trollers like p21Waf1 and p27Kip1 [31,35].
Induction of apoptotic cell death
The effect of NSAIDs on cell viability is drug- and
cell type-dependent. For example, we find that the
COX-2-selective inhibitor NS398 does not induce apo-
ptosis in lung cancer cells [36]. Similarly, the NSAID
rofecoxib exhibits little cytotoxic activity in vitro [37].
Conversely, the COX-2 inhibitor celecoxib effectively
causes apoptosis in colon cancer, cholangiocarcinoma
and prostate cancer cells [38–40]. We also demonstrated
that the apoptosis-inducing activity of NSAIDs is
associated with culture conditions, and cells main-
tained in low serum situation are more sensitive to
NSAIDs [41]. The main targets of NSAIDs to trigger
apoptosis include the bcl-2 gene family, survivin,
Mcl-1, caspases and some upstream mediators like
ceramide and AKT kinase [42–44].
Repression of angiogenesis
The most potent angiogenic growth factor is vascular
endothelial cell growth factor (VEGF). Overexpression
of COX-2 increases the production of eicosanoids like
prostaglandins and thromboxanes, which may induce
VEGF expression and promote tumor angiogenesis
[45,46]. Therefore, it is not surprising that inhibition
of COX-2 activity by celecoxib reduced angiogenesis
and tumor growth in vivo [47]. Interestingly, COX-2
inhibitors may also act via COX-2-independent tar-
gets to attenuate VEGF expression and angiogenesis
[48–50].
MOLECULAR MECHANISMS UNDERLYING
ANTIMETASTATIC ACTION OF NSAIDS
Metastasis is the process by which tumors in situ invade
the surrounding tissues and disseminate to distant
organs via the blood or lymphoid system. This process
involves the acquisition of cell motility, novel cell adhe-
sion properties, and extracellular protease activity.
Therefore, a tumor cell requires: (1) increased migra-
tion caused by reorganization in the cytoskeleton; (2)
a loss of cell-cell adhesion along with a gain of cell-
matrix interaction; and (3) increased expression and
activity of extracellular proteases to degrade the extra-
cellular matrix to allow cell migration and invasion.
Matrix metalloproteinases (MMPs), a family of zinc-
dependent endopeptidases that selectively degrade
components of the extracellular matrix, are involved
not only in tissue remodeling but also in tumor angio-
genesis and metastasis [51]. The MMP family consists
of at least 23 enzymes and may be subgrouped into
different types including collagenases, stromelysins,
gelatinases, matrilysin, membrane-type MMPs, and
metalloelastase, based on substrate specificity and
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sequence characteristics [52,53]. MMPs are synthesized
as inactive precursors and are activated by proteo-
lytic cleavage. Thus, MMP activity can be regulated
at three steps: (1) gene expression; (2) proenzyme
activation; and (3) direct inhibition of enzymatic
activity. The inhibition of MMPs by NSAIDs was first
reported by Abiru et al and our group [54,55]. Abiru
et al demonstrated that aspirin and NS398 suppressed
MMP-9 expression and activity and reduced hepato-
cyte growth factor-induced invasiveness of human
hepatoma cells. In addition, they found that inhibi-
tion of MMP-9 by NSAIDs was associated with the
repression of extracellular signal-regulated kinases
(ERKs). We similarly found that NS398 attenuated
MMP-2 expression in human lung cancer cells [55].
Interestingly, we also found that NS398 inhibited ERK
activation and then repressed Sp1-mediated tran-
scription of MMP-2. These studies suggest that ERKs
are critical targets for NSAIDs to suppress the expres-
sion of different MMPs to reduce the invasive ability
of cancer cells.
Our subsequent study elucidated the molecular
mechanism of NSAID-induced inhibition of ERKs.
We found that NS398 directly interfered with the
recruitment of Raf kinase, an upstream ERK activat-
ing kinase, by membrane-bound Ras protein, there-
fore attenuating growth factor-induced ERK activity
[56]. Moreover, we found that NSAIDs may increase
the expression of MAP kinase phosphatases to induce
dephosphorylation and inactivation of ERKs. In addi-
tion to regulating MMPs, NSAIDs also modulate the
expression and activity of MMP inhibitors. Several
proteins have been shown to exhibit potent inhibitory
activity against MMPs. These include tissue inhibitors
of metalloproteinase (TIMPs), domains of netrins, the
procollagen C-terminal proteinase enhancer (PCPE),
tissue factor pathway inhibitor (TFPI-2), and the newly
identified RECK [57–60]. Our recent study demon-
strated that NSAIDs may upregulate RECK and TIMP-
2 expression in human lung cancer cells to attenuate
tumor-associated MMP activity and invasion [61,62].
Taken together, MMPs and their inhibitors are critical
targets for NSAIDs to repress tumor invasion and
metastasis.
Another class of proteins involved in NSAID-
mediated inhibition of metastasis is matricellular
proteins. These proteins, including secreted protein
acidic and rich in cysteine (SPARC), thrombospondins
(TSPs), osteopontin, Cyr61 and connective growth
factor (CTGF), are secreted proteins that may interact
with the extracellular matrix, cell surface receptors,
growth factors and proteases [63]. Functional studies
suggest that matricellular proteins exhibit multiple
biological activities in the regulation of cell prolifera-
tion, apoptosis, angiogenesis, and tissue remodeling.
Among these members, SPARC and TSPs have been
shown to exert antiangiogenic and antimetastatic
functions. A pioneer work demonstrates that TSP-1 is
upregulated via transcriptional activation by COX-2
inhibitors [64]. Our recent study confirms this result
and indicates that SPARC and TSP-3 are also increased
by NSAIDs [62]. More importantly, we found that
NSAIDs activate SPARC expression via a unique
mechanism, promoter demethylation [62]. Epigenetic
silencing by DNA methylation of tumor suppressor
genes (like SPARC and TSPs) is a general event found
in cancer cells [65]. Promoter methylation is catalyzed
by DNA methyltranferases (DNMTs), which are fre-
quently increased in cancer cells. We demonstrated for
the first time that NSAIDs may suppress the expres-
sion of DNMTs, which leads to demethylation of the
SPARC promoter and reactivation of SPARC expression
in human lung cancer cells [62]. These results suggest
that NSAIDs function as a new class of demethylating
drugs and may be useful in epigenetic therapy.
Although a number of targets that mediate the
antimetastatic action of NSAIDs have been identified,
the list is still increasing. For example, our unpub-
lished results indicate that NSAIDs may also control
the expression of cell adhesion molecules to affect the
migration and invasion of cancer cells. Identification
of all targets may give us a whole picture of NSAID-
induced inhibition of metastasis and provide more
strategies for cancer treatment.
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腫瘤組織均會過度表現，同時可經由 (1) 刺激癌細胞增生，(2) 增加腫瘤血管新生，
(3) 降低癌細胞凋亡，(4) 調節免疫反應及 (5) 增進癌症轉移以促使腫瘤生成。可預期
的，非類固醇抗發炎藥物可能藉由抑制這些步驟以減少癌症發生。在此綜論，我們討
論非類固醇抗發炎藥物之抗癌機制，尤其深入闡釋這些藥物如何抑制癌症轉移。
非類固醇抗發炎藥物之抗腫瘤轉移作用
洪文俊
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